Episode Details
Back to Episodes
Pfizer's Q1 2026 Earnings: Vyndamax Patent Win, Pipeline Focus
Published 1 day, 2 hours ago
Description
Pfizers Q1 2026 earnings report looms, with Goldman Sachs lowering price target to $26. Pfizer aims for $59.5-62.5B revenue, $2.80-3.00 EPS, despite Covid and patent loss impacts. Vyndamax patent settlement delays U.S. competition until 2031. Investors seek growth beyond cost savings and patent breather for stock boost.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/3b60f09e92442cc1